International medical researchers have confirmed that Long COVID fundamentally disrupts cellular energy production at the mitochondrial level, while also revealing a previously underappreciated mechanism by which SARS-CoV-2 directly damages nerve cells through TRPV1 activation—findings that carry significant implications for the estimated hundreds of thousands of Thailand residents still coping with post-viral symptoms. Several Thai hospitals are now participating in international treatment trials investigating these discoveries.
Why This Matters
• Mitochondrial dysfunction is now confirmed as a central driver of chronic fatigue and brain fog in Long COVID, not simply lingering inflammation.
• Emerging targeted therapies currently in clinical trials, including investigational monoclonal antibodies and NAD+ precursor compounds, show promise for improvements in energy levels within 8-12 weeks in trial participants. Most advanced treatments are not yet standard care but available through research initiatives.
• SARS-CoV-2 directly infects TRPV1-expressing sensory neurons, triggering axonal degeneration that contributes to loss of smell and potential cognitive impairment.
• Treatment access in Thailand: Several clinical trials investigating mitochondrial restoration and anti-inflammatory protocols are ongoing at Thai hospitals, with results expected through 2026. These trials offer access to cutting-edge therapies for eligible participants.
Cellular Powerhouses Under Siege
At the heart of the Long COVID energy crisis lies the mitochondrion—the organelle responsible for producing adenosine triphosphate (ATP), the molecular currency that fuels every cellular function from muscle contraction to brain activity. Studies conducted through 2025 and into 2026 have consistently documented structural damage to mitochondria in patients months after their initial infection cleared, including swelling and disrupted cristae visible under electron microscopy.
The initial COVID-19 infection sets off a cascade: chronic inflammation, immune system dysregulation, and oxidative stress converge on the mitochondria, impairing their ability to generate energy efficiently. Research indicates the virus may directly interfere with mitochondrial machinery, causing transcriptional repression of mitochondrial genes and forcing cells to rely on glycolysis—a far less efficient energy pathway than oxidative phosphorylation.
Blood analyses from 2025 revealed persistent disruptions in cellular metabolism and signs of chronic inflammation in Long COVID patients. Elevated levels of peroxiredoxin-3 (PRDX3), a mitochondrial stress biomarker, point to ongoing oxidative damage and impaired mitochondrial quality control. Immune cells from these patients exhibit abnormal ATP synthase behavior, the enzyme crucial for energy production, with dysfunction severity correlating directly to reduced quality of life and clinical symptom burden.
The TRPV1 Connection: How Smell Loss Signals Deeper Damage
Beyond energy disruption, recent findings have uncovered a distinct pathway of neurological harm. SARS-CoV-2 directly infects TRPV1-expressing sensory neurons, including those in the olfactory system responsible for smell. Exposure to the live virus or its S1 spike protein upregulates TRPV1 expression and induces its translocation from the nucleus to the cytosol, subsequently triggering axonal destruction.
This mechanism helps explain the persistent anosmia (loss of smell) reported by thousands of Thailand COVID-19 survivors. Single-nucleus transcriptomic analysis revealed that viral exposure enhances cAMP signaling, virus receptor activity, and inflammatory regulation of TRP channels, all contributing to synaptic and axonal damage. Critically, treatment with a TRPV1 antagonist demonstrated neuroprotective effects in laboratory models, inhibiting activation and mitigating axonal damage in sensory neurons exposed to SARS-CoV-2.
The damage extends beyond smell. Inflammation triggered by SARS-CoV-2 infection in the olfactory epithelium damages neurons and reduces the number of axons transmitting signals to the brain, leading to olfactory bulb dysfunction—a process that may impair broader cognitive function and brain activity.
What This Means for Residents
For Thailand residents experiencing Long COVID symptoms—particularly debilitating fatigue, brain fog, reduced physical stamina, and impaired recovery after exertion—these findings are opening new treatment pathways through research initiatives. While most advanced therapies remain in clinical trial phases rather than standard care, participating in trials may provide access to cutting-edge treatments.
Mitochondrial restoration therapies are being investigated in trials. These treatments utilize specialized compounds, including NAD+ precursors and targeted Coenzyme Q10 formulations, to repair cellular energy production. Clinical trial data indicates trial participants receiving these therapies show improvements in energy levels within 8-12 weeks of treatment initiation. Nutritional strategies focusing on mitochondrial health are also under investigation, with compounds like creatine monohydrate, N-Acetylcysteine (NAC), pyrroloquinoline quinone (PQQ), omega-3 fatty acids, and Urolithin A being studied for their potential to support energy metabolism and reduce oxidative stress.
The Thailand Ministry of Public Health has recognized Long COVID as a priority health issue, with several hospitals in Bangkok, Chiang Mai, and Phuket participating in international research initiatives. The RECOVER Initiative, which completed enrollment for 8 clinical trials in 2025 investigating 13 potential treatments, is expected to release further results in 2026. Additionally, the MitoLoCo trial (NCT07134673), updated as recently as April 2026, is actively quantifying mitochondrial oxygen use in various tissues of Long COVID patients.
Treatment Trials and Options Under Investigation
The research landscape for Long COVID has evolved rapidly, with multiple clinical trials now evaluating potential therapies. Investigational monoclonal antibody therapies are being studied for their ability to address inflammatory pathways perpetuating symptoms, deploying customized anti-inflammatory approaches based on individual cytokine patterns.
Fluvoxamine, a widely available antidepressant, showed promise in a randomized, placebo-controlled clinical trial published in March 2026, significantly reducing fatigue and improving quality of life for adults with Long COVID. For patients experiencing postural orthostatic tachycardia syndrome (POTS)-like symptoms, pyridostigmine demonstrated improvements in exercise capacity and orthostatic intolerance in trial settings.
Brain-targeted medications that cross the blood-brain barrier are being investigated to tackle inflammatory processes in neural tissue, addressing the brain fog and cognitive issues that disrupt daily life for many patients. Low-dose naltrexone (LDN) is under investigation for its ability to modulate neuroinflammation by affecting microglial activation, with early trial data suggesting potential improvements in fatigue, pain, brain fog, and sleep quality.
Other therapies under investigation include semaglutide (a GLP-1 receptor agonist), taurine supplementation for enhancing cellular energy and vascular function, and anticoagulant therapy combinations, which showed potential improvements in some trial participants with cognitive dysfunction and fatigue.
Overlaps With Chronic Fatigue Syndrome
The molecular features of Long COVID—particularly impaired mitophagy (the process of removing damaged mitochondria), reduced mitochondrial enzyme activity, and oxidative damage—show significant overlap with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Both conditions share immune dysregulation, neuroinflammation, mitochondrial dysfunction, and autonomic nervous system disruption as core mechanisms.
This biological similarity has prompted Thailand medical institutions to adapt existing ME/CFS management protocols for Long COVID patients. Pacing—carefully matching activity levels to energy capacity to prevent symptom flares—remains a cornerstone of management for patients experiencing post-exertional malaise (PEM). For Long COVID patients without PEM, carefully adjusted exercise therapy has shown benefits in improving lung function and emotional well-being, but pushing through PEM can be harmful.
Lower levels of circulating cell-free mitochondrial DNA (ccf-mtDNA) in 2026 research possibly indicate impaired mitochondrial quality control and increased inflammation, providing a potential biomarker for disease severity and treatment response.
What Hasn't Worked
Not all investigated treatments have proven effective. Long-term courses of Paxlovid did not show improvement in Long COVID symptoms in the RECOVER-VITAL trial published in March 2026. While metformin demonstrated effectiveness in preventing Long COVID if administered within 3 days of acute COVID-19 infection, it did not prove effective as a treatment for established Long COVID in the RECOVER ENERGIZE trial.
Practical Steps Forward and Accessing Care in Thailand
Effective management of Long COVID in Thailand often involves a multidisciplinary team and personalized rehabilitation. This includes autonomic support measures like increased hydration, appropriate salt intake (particularly important in Thailand's tropical climate where heat and humidity can exacerbate POTS and orthostatic symptoms), and the use of compression garments for orthostatic intolerance. Environmental considerations in urban areas like Bangkok—such as air quality and pollution—may also require attention, as poor air quality can worsen respiratory and fatigue symptoms.
Lifestyle adjustments such as good sleep hygiene, stress reduction, stable meal patterns, and gradual movement tailored to individual energy capacity are crucial components.
For Thailand residents seeking treatment access: The NIH RECOVER-Treating Long COVID (RECOVER-TLC) initiative and related trials are actively recruiting participants at major Thai hospitals in Bangkok, Chiang Mai, and other urban centers. If you have Long COVID symptoms, you can contact your nearest participating hospital to inquire about trial enrollment and eligibility. Most trials offer evaluations and potential access to investigational treatments at no cost to participants, though out-of-pocket diagnostic testing may apply depending on the specific trial and your insurance coverage.
• For Thai nationals: Care through public hospitals participating in trials is typically covered or subsidized through the Thai social security system.
• For expats and private insurance holders: Contact your insurance provider to determine coverage for trial participation and related consultations. Many private hospitals in Bangkok (Bumrungrad, Samitivej, Bangkok Hospital) have Long COVID programs and can provide information about available trials and treatment options. Costs typically range from moderate consultation fees to complete coverage depending on your policy.
• For uninsured residents: Some public hospital trials offer free evaluation and treatment, though availability varies. The Ministry of Public Health website maintains updated information on participating facilities.
Consulting with specialists at hospitals participating in these research initiatives may provide access to cutting-edge therapies and clinical trial enrollment—currently the primary avenue for accessing the most advanced Long COVID treatments in Thailand.
The convergence of mitochondrial dysfunction research and TRPV1-mediated nerve damage findings offers a more complete picture of Long COVID's biological mechanisms—and, importantly, actionable treatment pathways and trial opportunities for the hundreds of thousands of Thailand residents still navigating this complex post-viral condition.
